<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1521">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412317</url>
  </required_header>
  <id_info>
    <org_study_id>VIGIL</org_study_id>
    <nct_id>NCT04412317</nct_id>
  </id_info>
  <brief_title>Use of PCR-Sars-CoV-2 in Children</brief_title>
  <acronym>VIGIL</acronym>
  <official_title>National Observatory of the Care of Young Sick Children in Community or Not, Indications and Cost-effectiveness of PCR-Sars-CoV-2 - VIGIL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Clinique Thérapeutique Infantile du val de Marne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GPIP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AFPA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GFRUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to clarify the current management of young sick children in France, whether or not
      they are cared for in community settings (nursery, schools), paediatricians have proposed an
      algorithm whose objective is to help define the indications for PCR-Sars-CoV-2
      (https://www.infovac.fr/actualites/bulletin-special-mai-2020).

      This algorithm, in two parts, can be used, when symptoms are detected in children, to orient
      and guide :

        -  first, parents and community personnel to recognize the signs of infection call signs
           that should involve medical consultation;

        -  but also, the physicians who will carry out this medical evaluation and will have to
           decide whether or not PCR screening is necessary, in parallel with their diagnostic and
           therapeutic management, which should not be altered in this particular context

      Our main objective is to describe, after the confinement phase, the management of young sick
      children in the community (crèches, nursery and elementary schools, etc.) or not in order to
      best define the indications for PCR-Sars-CoV-2
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of children screened with a positive PCR result</measure>
    <time_frame>the day of PCR result</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of PCR-Sars-CoV-2 positive in the sick child in the presence of a Covid contagion in the family environment or not</measure>
    <time_frame>the day of PCR result</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Children &lt; 15 years old</arm_group_label>
    <description>Patients under 15 years old who consults a physician on an outpatient basis or in the emergency room and who requires a Sars-CoV-2 RT- PCR (nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction) diagnostic</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Child from birth to 14 years of age consulting their doctor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children under 15 years of age

          -  Prescription of a PCR-Sars-CoV-2

          -  VIGIL information note given to parents

        Exclusion Criteria:

          -  Refusal to participate by the patient, family member or legal representative
             (depending on the situation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corinne Levy, MD</last_name>
    <phone>148850404</phone>
    <phone_ext>33</phone_ext>
    <email>corinne.levy@activ-france.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ACTIV network</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne LEVY, MD</last_name>
      <phone>148850404</phone>
      <phone_ext>33</phone_ext>
      <email>corinne.levy@activ-france.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PARI network</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Levy, MD</last_name>
      <email>corinne.levy@activ-france.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

